Thymalin

Thymalin is a polypeptide complex of low molecular weight (up to 10 kDa) isolated from the thymus glands of calves. Its active pharmaceutical constituents include a mixture of short peptide fragments, among which the dipeptides KE (Lys-Glu) and EW (Glu-Trp) have been most extensively studied in recent molecular analyses.

The primary immunomodulatory mechanism involves promotion of hematopoietic stem cell differentiation toward mature T-lymphocyte lineages. In a 2021 randomized controlled trial by Khavinson et al. published in Stem Cell Reviews and Reports, the authors attributed Thymalin's clinical effects to enhanced HSC maturation into CD28-expressing T cells, leading to measurable increases in circulating CD4+ T-cell counts. The preparation modulates the CD4+/CD8+ ratio and has been reported to elevate natural killer cell activity.

At the molecular level, computational docking and gene-expression studies published in the International Journal of Molecular Sciences (2023) identified 24 COVID-19-associated gene targets for the KE and EW dipeptides. KE is proposed to bind double-stranded DNA and histone proteins, thereby regulating transcription of genes involved in cellular immunity; its principal identified genomic target is CHUK, a regulator of the NF-kB pathway. EW targets ACE2 and CYSLTR1 gene promoters and inhibits angiotensin-converting enzyme activity, preserving endothelium-dependent vascular relaxation. Both dipeptides share AKT1 and AKT2 as downstream targets.

In vitro, KE and EW reduced LPS-stimulated TNF-alpha production 5-6 fold and IL-6 approximately 2.5 fold in human peripheral blood mononuclear cells, suggesting a significant anti-inflammatory action alongside the pro-T-cell effects.

The bulk of published human research on Thymalin originates from a single Russian institution, the St. Petersburg Institute of Bioregulation and Gerontology, primarily from the laboratory of Professor Vladimir Khavinson. This geographical and institutional concentration is an important limitation when evaluating the evidence base.

The most-cited long-term study is Khavinson and Morozov (2003), published in Neuro Endocrinology Letters (PMID 14523363), which followed 266 elderly participants (average age 71-77 years) over 6-8 years at two Russian centers. Participants received Thymalin alone, Epithalamin (a pineal gland extract) alone, the combination, or no peptide treatment during the first 2-3 years. Thymalin alone was associated with a 2.0-2.1-fold reduction in mortality compared with controls. The subgroup receiving annual 10-day courses of both Thymalin and Epithalamin for 6 years showed a 4.1-fold lower mortality. Respiratory infection incidence decreased 2.0-2.4 fold in treated groups. Improvements in cardiovascular, endocrine, immune, and nervous system parameters were also reported. The study was open-label, conducted at Russian gerontology institutes, and has not been independently replicated outside Russia.

A prospective, randomized single-center controlled trial conducted in April-July 2020 at St. Petersburg City Hospital No. 2 (Khavinson et al., Stem Cell Reviews and Reports, 2021; DOI 10.1007/s12015-020-10087-6; PMID 33575961) assigned 42 patients with severe COVID-19 to standard therapy plus Thymalin 10 mg IM once daily for 5 days, with 50 patients in the standard-therapy control. At end of follow-up, the Thymalin group showed a 5.5-fold decrease in IL-6 (versus 1.4-fold in controls), a 55% increase in lymphocytes, an 88.9% increase in CD4+ T cells, a 5.7-fold reduction in D-dimer, and a 9.7-fold reduction in C-reactive protein. Disease progression was observed in 2 Thymalin-treated patients versus 5 controls; no deaths occurred in either group. The trial was small (n=92), unblinded to treating clinicians, and single-center.

Animal and in vitro data, including a 2023 study in the International Journal of Molecular Sciences (PMC10488166), support the anti-inflammatory cytokine effects through computational modeling and PBMC assays using samples from only 4 healthy donors, representing preliminary mechanistic evidence rather than clinical proof of efficacy.

Typical dosage: 10 mg (daily for 10-day cycles).

Dosage information for Thymalin is drawn from Russian pharmaceutical labeling and the published clinical trials described above. No FDA-approved labeling exists, and Western regulatory guidance is absent.

In the 2021 COVID-19 randomized trial, the protocol was 10 mg administered intramuscularly once daily for 5 consecutive days (total course: 50 mg). This represents the best-documented published human dosing regimen.

In the 6-8-year longevity study (Khavinson and Morozov 2003), courses were described as 10-day injection cycles, with some participants receiving annual repeat courses; specific per-dose amounts were not reported in the published abstract.

Russian pharmaceutical sources describe standard clinical courses as 5-10 mg intramuscularly or subcutaneously once daily for 5-10 days, with total course doses ranging from 25 to 100 mg. Courses are typically repeated once or twice per year in aging or immune-support contexts. Some Russian institutional protocols specify a dose of 10 mg per day for 10 days (100 mg per course) when used for geroprotection or chronic immune insufficiency.

Outside Russia, Thymalin circulates in compounding and "research peptide" markets. Community discussions report protocols mirroring the Russian clinical literature: 5-10 mg per day subcutaneously or intramuscularly, in 5-10-day cycles, 1-2 times annually. These community-use reports are anecdotal and have no independent safety monitoring.

The compound is not approved for human use by the FDA, EMA, or comparable Western regulatory agencies. This information is provided for educational reference only and does not constitute medical advice. Anyone considering use of Thymalin should consult a qualified physician.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The most extensively studied combination in the peer-reviewed literature is Thymalin with Epithalamin, a polypeptide extract of the pineal gland. In the Khavinson and Morozov (2003) longevity trial, the combination produced a 4.1-fold mortality reduction over 6 years compared to controls, markedly exceeding the 2.0-2.1-fold reduction seen with Thymalin alone. The rationale is complementary organ targeting: Thymalin is proposed to restore thymic immune signaling while Epithalamin addresses age-related decline in pineal melatonin rhythmicity and neuroendocrine regulation.

Vilon (the Lys-Glu dipeptide, also a thymic bioregulator) is sometimes discussed alongside Thymalin in the Russian peptide bioregulator literature as a shorter-acting companion compound, though no published human trial specifically examines their co-administration.

In the Western compounding and longevity community, Thymalin is occasionally stacked with Thymosin Alpha-1 (Ta1), on the rationale that Ta1 acts on mature dendritic cells and antigen presentation while Thymalin addresses upstream T-cell generation. This combination is anecdotal; no controlled study of this pairing has been published. Similarly, combinations with Epitalon (the synthetic tetrapeptide analog of Epithalamin) are widely discussed in longevity forums, but direct RCT evidence is lacking; the Khavinson longevity data used the crude pineal extract Epithalamin, not the synthetic tetrapeptide Epitalon.

Thymalin is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Well-tolerated during cycles

Based on the published clinical studies and Russian pharmaceutical experience spanning more than four decades, Thymalin has a favorable acute safety profile. In the 2021 randomized COVID-19 trial (n=92 total, 42 receiving Thymalin), no deaths in either group were attributed to the drug, and no serious adverse events were specifically reported in the Thymalin arm. Disease progression occurred in fewer Thymalin-treated patients (2 vs. 5 controls).

The most commonly noted adverse effect in Russian clinical reports is mild injection site reactions, including transient redness and discomfort following intramuscular administration. Fatigue during the first days of a course has been mentioned in case reports and clinical summaries. Systematic adverse event collection in Western regulatory trials has not been performed.

Several theoretical safety concerns deserve explicit acknowledgment:

• As a bovine tissue-derived extract, Thymalin carries a theoretical risk of prion disease transmission (bovine spongiform encephalopathy). Russian pharmaceutical manufacturing standards address this through source-herd certification, but third-party or compounded preparations may not offer equivalent assurances.

• Autoimmune conditions represent a potential contraindication. The immunostimulatory effects of Thymalin could theoretically exacerbate autoimmune disease activity; use in patients with rheumatoid arthritis, lupus, multiple sclerosis, or other autoimmune disorders is not supported by safety data and should be approached with caution, if at all.

• Concomitant use with immunosuppressive therapies (e.g., corticosteroids, calcineurin inhibitors, biologic agents) is pharmacologically counterproductive and has not been studied.

• Safety in pregnancy, lactation, pediatric populations, and patients with active malignancy has not been systematically evaluated in published trials.

• No pharmacokinetic data (half-life, volume of distribution, metabolic pathways) have been published in indexed English-language literature.